Zukhra Khasanshina

Ms. Zukhra Khasanshina


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Problems of Nutrition
Verified
Journal Article
Closed access
PMPavel Alexandrovich Markov
Pavel Alexandrovich Markov
MVMarina Volkova
Marina Volkova
ZKZukhra Khasanshina
Zukhra Khasanshina
EME.A. Martinson
E.A. Martinson
SPSergey Popov
Sergey Popov
Противовоспалительное действие высоко- и низкометилэтерифицированных яблочных пектинов in vivo и in vitro

5 June 2023 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
IKI. A. Kornakov
I. A. Kornakov
ZKZukhra Khasanshina
Zukhra Khasanshina
DSD. A. Senichkina
D. A. Senichkina
AFA. A. Filipenko
A. A. Filipenko
ILI. S. Lunev
I. S. Lunev
RDRoman Drai
Roman Drai
Diabetes poses a serious threat to the health of people around the world. Therefore, in 2021, the World Health Organisation launched the Global Diabetes Compact, an initiative aimed at improving the management and prevention of diabetes. The rapid growth in the number of diabetic patients has increased the need for insulin. Rapid-acting human insulin analogues, including insulin aspart, improve the efficacy of insulin therapy. Methods for insulin aspart production include its biosynthesis in the proinsulin form in Escherichia coli. However, the yield of the recombinant protein largely depends on the optimisation of the production process.The aim of the study was to optimise the induction conditions for an E. coli strain expressing recombinant proinsulin aspart through applying the Design of Experiment (DoE) approach to enhance bacterial cell productivity.Materials and methods. The study focused on a strain of E. coli producing proinsulin aspart. The authors planned the experiment using MODDE software and the reduced face-centred central composite design (CCF) enabling the assessment of factor interactions and the creation of design spaces. The authors carried out fermentations of the producing strain in a 5 L Biostat® B bioreactor and measured proinsulin aspart concentrations by capillary gel electrophoresis. The results were analysed using GraphPad Prism 6.Results. Using the DoE approach, the authors optimised the conditions for the growth of the producer strain and the biosynthesis of proinsulin aspart. Based on data from response surface plots for wet biomass concentration, specific productivity, and volumetric productivity, as well as plotted models, the authors established design spaces for the induction of proinsulin aspart expression in E. coli. The plotted models demonstrated high predictive power and high reproducibility of the results. The authors successfully validated the induction process for the synthesis of proinsulin aspart in a bioreactor under optimised conditions. The volumetric productivity of the strain producing proinsulin aspart increased from 3.06±0.16 g/L (conventional conditions) to 4.93±0.80 g/L (optimised conditions).Conclusions. The authors achieved a 60% increase in the volumetric yield of proinsulin aspart. The study results may be used to intensify the industrial production of insulin aspart.

1 January 2022 in Biotekhnologiya
Verified
Journal Article
Closed access
ZKZukhra Khasanshina
Zukhra Khasanshina
ИЛИ. С. Лунев
И. С. Лунев
АФА. А. Филипенко
А. А. Филипенко
СТС. С. Тимофеев
С. С. Тимофеев
ВЛВ. Ф. Латыпов
В. Ф. Латыпов

27 January 2025 in Drug development & registration
Verified
Journal Article
Open access
PDF file
ZKZukhra Khasanshina
Zukhra Khasanshina
IKI. A. Kornakov
I. A. Kornakov
EBE. A. Buslaeva
E. A. Buslaeva
AKA. V. Kazakova
A. V. Kazakova
SIS. A. Ishchuk
S. A. Ishchuk
RDRoman Drai
Roman Drai
Introduction. Peptides with a molecular weight of less than 5 kDa have been used in medicine and biotechnology over the past decade for the treatment of various diseases. However, chemical synthesis peptide has several disadvantages, including low yield, reduced efficiency, and high costs. An alternative approach to peptide production is the use of the Escherichia coli expression system. The development of effective peptide synthesis technology remains a critical task because of the low productivity of recombinant strains.Aim. Developing highly efficient strains of Escherichia coli BL21 expressing therapeutic peptides with a molecular weight of less than 5 kDa in E. coli and their cultivation technology.Materials and methods. Genetic constructs were obtained using the restriction-ligase method, and their authenticity was confirmed by Sanger sequencing. Cultivation technology was developed using the Design of Experiments approach. The cultivation condition was validated in the Biostat B bioreactor. Hybrid proteins were purified by metal-chelate chromatography, followed by hydrolysis ULP proteas to obtain the target peptides. The quantitative content of the target protein was determined by capillary electrophoresis, and the authenticity of the protein was confirmed by HPLC-MS and ELISA.Results and discussion. Highly efficient peptide-producing strains were developed. Cultivation conditions were optimized: рН 7.5 ± 0.5, cultivation temperature 37 °C, induction optical density 28 ± 2, IPTG concentration 0.05 мМ. The productivity of the producer strains was up to 4.82 ± 0.05 g/L. Furthermore, samples of the target peptides were isolated and purified.Conclusion. The productivity of peptides in this study were significantly higher than in previous research. The presented strategy for strain development, cultivation and purification technology can be used production of therapeutic peptides with diverse physical chemicals characteristics in the future.

2 March 2026 in Drug development & registration
Verified
Journal Article
Open access
PDF file
AKA. S. Kazakova
A. S. Kazakova
AAA. N. Afanaseva
A. N. Afanaseva
AEA. A. Evreiskaya
A. A. Evreiskaya
AAA. D. Akino
A. D. Akino
AZA. K. Zenkova
A. K. Zenkova
RDRoman Drai
Roman Drai
Introduction. About 30 % of genetically engineered therapeutic proteins are produced in Escherichia coli . In the production of these proteins, cell viability is one of the key factors determining process efficiency and product quality. Controlling viability is essential when creating cell banks and optimizing E. coli cultivation conditions. Changes in cultivation parameters can affect viability and lead to shifts in the proportions of viable cells, dead cells, and cells undergoing apoptosis-like death (ALD). Flow cytometry is one method used to assess viability and distinguish between different cell populations. Aim. To develop, validate and test a methodology for assessing the viability of E. coli using flow cytometry. Materials and methods. To assess cell viability, we stained E. coli with propidium iodide (PI) and annexin V-FITC (An-V-FITC). We identified populations of live, dead, and ALD cells using dual staining with PI and An-V-FITC. The method was validated in accordance with the State Pharmacopoeia, the Decision of the EEC Council No. 85 dated 03.11.2016, and ICH guidelines. We evaluated the method’s applicability in developing conditions for cell bank creation and cultivation. Results and discussion. We developed a method for assessing the viability of E. coli cells using flow cytometry and dual staining with PI and An-V-FITC, which enables the identification of live, dead, and ALD cell populations. Validation results demonstrated that the method meets the criteria: specificity (6 %), linearity ( R 2 > 0.9), accuracy (97–102 %), the limit of quantification (confirmed, 117 %), repeatability (1–10 %), intra-laboratory precision (2–17 %), analytical range (6.4–100 %). In selecting optimal conditions for cell bank creation, viability assessment enabled us to determine the optimal ratio of culture fluid to cryoprotectant (3 : 1) at an optical density of OD 600 = 15, resulting in over 97 % viable cells after cryopreservation. During strain cultivation process development, the method facilitated the selection of optimal conditions. In the bioreactor, the proportion of dead cells increased by only 2.5 %, and the proportion of ALD cells increased by 7 % after 8 hours of induction. Conclusion. We developed and validated a methodology for assessing E. coli viability that can be used during the development and production of therapeutic products.

1 June 2026 in Applied Biochemistry and Microbiology
Verified
Journal Article
Closed access
PDF file
DGD. A. Grechko
D. A. Grechko
MBM. D. Bochkareva
M. D. Bochkareva
ADA. V. Dvoretskaya
A. V. Dvoretskaya
ZKZukhra Khasanshina
Zukhra Khasanshina
RDRoman Drai
Roman Drai
In this study, genetically modified Escherichia coli strains FS60 and FS61 were constructed, engineered for overexpression of acetyl-CoA synthetase (ACS) under promoters of different strengths. Since ACS catalyzes the activation of acetate to acetyl-CoA, its overexpression was hypothesized to alter acetate accumulation and influence recombinant protein formation. Comparative cultivations of these strains in bioreactors were performed alongside the industrial reference strain E. coli BL21. The study aimed to evaluate the effect of ACS overexpression on the accumulation of the toxic secondary metabolite, acetate, and the productivity of the target recombinant protein. Significant reductions in acetate accumulation were observed in E. coli FS61: 66 and 73% at 3 and 4 h after induction, respectively, relative to that in E. coli BL21 during high-density fermentation. In contrast, E. coli FS60, expressing ACS under a stronger promoter, exhibited only 20 and 4% decreases in acetate accumulation at the same time points. These results may indicate that excessive ACS expression under a strong promoter imposes a metabolic burden, possibly disturbing energy flux and, in turn, promoting acetate synthesis rather than its utilization. By comparison, moderate expression driven by the Tac promoter appeared to reduce extracellular acetate accumulation more effectively. Reduced acetate accumulation correlated with improved recombinant protein productivity. ACS overexpression enhanced specific productivity of the target protein in E. coli FS60 by 28 and 40% at 3 and 4 h after induction, respectively, and by 59 and 51% in FS61. However, both genetically engineered strains demonstrated reduced biomass accumulation compared to E. coli BL21, limiting volumetric productivity. This effect may be attributed to the additional metabolic burden imposed by ACS overexpression, which decreases the growth rate of the engineered strains. In conclusion, ACS overexpression enhances cell-specific productivity, but requires further optimization to achieve volumetric productivity comparable to the industrial E. coli BL21 strain. This approach holds promise for industrial biotechnology applications although cultivation conditions require refinement to mitigate metabolic burden and maximize production efficiency.